Effective Management of Chemotherapy-Induced
Nausea and Vomiting (CINV): Appropriate
Treatment for Improved Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Helsinn

Chemotherapy-induced nausea and vomiting (CINV) is a condition in which patients become physically ill following the administration of chemotherapy drugs and is one of the most feared side effects of chemotherapy treatments. Patients who suffer from acute CINV typically experience symptoms within the first 24 hours following treatment while delayed CINV usually occurs within 24 to 72 hours after chemotherapy and can potentially last for several days. Risk factors for this condition fall into patient-specific and therapy-specific categories thus the treatment of CINV can vary depending on the patient’s response to the therapy introduced after chemotherapy. Utilizing an appropriate degree of prophylaxis for the first cycle of chemotherapy is critical to prevent breakthrough CINV, which is difficult to manage and can lead to later anticipatory vomiting during subsequent cycles of therapy. The goal of selecting optimal antiemetic therapy continues to be based on the patient’s individualized treatment plans with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of CINV. Optimizing antiemetic usage requires awareness of available and emerging agents, as well as of the unique characteristics of these therapies that affect their role in CINV management. Because antiemetic medication has such a high success rate, chemotherapy patients no longer have to accept nausea, vomiting, and a decreased quality of life as an automatic consequence of treating cancer.

Upon completion of this activity, participants will be able to:

  • Analyze the impact, occurrence and risk of CINV with commonly used chemotherapy regimens

  • Examine the emerging clinical trial data for the safety and efficacy of newly approved agents

  • Review the current and emerging chemotherapeutic agents for the treatment of CINV

  • Differentiate antiemetic regimens for acute, delayed, breakthrough, and refractory CINV

  • Identify educational tactics to promote effective communication and coordination of care, address potential adverse events, and help patients improve CINV outcomes

Faculty: Susan Urba, MD
Professor of Internal Medicine
Division of Hematology/Oncology
Medical Director
Symptom Management & Supportive Care Program
University of Michigan Comprehensive Cancer Center


Dr. Urba has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from Helsinn

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue